Archivo Eventos
Development of Carbon Nanotubes-based Hydrogels for Nerve Tissue Regeneration
Nerve trauma often results in severe sensory and motor function loss due to axonal damage and demyelination. Current strategies aim to prevent neuromas formation and support guided nerve regeneration. Hydrogels, owing to their biomimetic properties, offer a promising platform for such applications. The thesis introduces three novel hydrogel types: PVA/CNT
Dr Bock’s research applies bioengineering strategies to study the bone organ and tumours in this microenvironment with the ultimate goal of identifying new mechanisms that may ultimately help to understand, prevent and treat disease. The specific focus is to develop and use biomimetic 3D tailorable tissue model systems for in
Inmunoterapia del cáncer basada en células NK
La inmunoterapia del cáncer utiliza el sistema inmunitario para eliminar células tumorales, y las células NK (natural killer) desempeñan un papel clave en este proceso. Estas células del sistema inmunitario innato pueden reconocer y destruir células cancerosas sin necesidad de sensibilización previa. Actualmente, se están realizando ensayos clínicos que emplean
Primary sclerosing cholangitis (PSC) is the most significant risk factor for the development of cholangiocarcinoma (CCA); up to 20% of patients with PSC develop CCA during their lifetime. Currently, the accuracy of diagnostic methods for PSC-CCA is far from satisfactory, resulting in late-stage disease diagnosis, when no curative treatments are
Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) / HER2-negative (HER2-) breast cancer (BC) allows real-time evaluation of treatment sensitivity and offers the opportunity of personalised BC therapy. However, the lack of reproducible biomarkers to assess response and long-term prognosis after NET is a significant barrier to increase its indications.
Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) / HER2-negative (HER2-) breast cancer (BC) allows real-time evaluation of treatment sensitivity and offers the opportunity of personalised BC therapy. However, the lack of reproducible biomarkers to assess response and long-term prognosis after NET is a significant barrier to increase its indications.